Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B in Perimenopausal Women.

Inclusion Criteria: * Female subjects, 50 years of age or younger; * Subjects in the second phase of menopausal transition as per STRAW 10+ i.e. interval of amenorrhea 60 days or more (with regular menstrual cycle during earlier reproductive stages). * Subjects with diagnosis of mild to moderate climacteric syndrome; * Recent (up to 12 months prior to study enrollment) breast exam results, including mammogram, that rule out malignancies; * Recent (up to 3 years prior to study enrollment) cytological screening that rules out vaginal cervix malignancies. * Ability to read and understand informed consent form for the study's participation; * Ability to adhere to the conditions of the study. Exclusion Criteria: * • Postmenopause, including surgical menopause. * Presence of hormone-dependent cancers; * Presence of other cancers, not in full remission with no recurrence for 5 years or more; * Planned hospitalization in the next 6 months; * Presence of hormonally-active extragenital endocrine diseases (diabetes; diseases of thyroid, adrenal, pituitary) that require prolonged or life-long therapies * Surgical interventions on sex organs or breasts, 1 year or less prior to the screening; * Gynecological conditions that may require hormonal therapies or surgeries (uterine myoma, endometriosis, endometrial hyperplasia etc.); * Currently undergoing or planning to utilize assisted reproductive technologies; * Any abdominal surgeries within less than 3 mont…